Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HHSE Board of Directors approves Uplisting / Registration Costs
Dear HHSE Friends, Followers & Shareholders: At a special meeting of the Board of Directors of Hannover House, Inc., held on Thursday, October 19 at 11:00-am, the Board voted unanimously to immediately reinstate the prior filing activities to register the company's stock shares with the Securities and Exchange Commission (Form 10). The Board also authorized the following budgetary expenditures - to be funded from ongoing cash flows - to promptly complete this task:
HHSE
Steps and Budget for UPLISTING
Item
Description
Amount
1
Internal Data Entry
$ 4,000
2
Completion of New Library Valuation
$ 20,000
3
Outside CPA Review
$ 4,500
4
PCAOB Audit
$ 50,000
5
Legal Review & Drafting
$ 6,500
6
Registration S.E.C. Filings & XBRL
$ 3,250
FIRST TIME - UPLIST REGISTRATION COSTS
$ 88,250
Ongoing Quarterly Auditor's Review
$ 5,000
Ongoing Quarterly Attorney's Review
$ 2,000
Annual Review of Q4 & prior 3-Q's
$ 20,000
Annual Attorney review and drafting
$ 3,000
ANNUAL MAINTENANCE TOTALS
$ 44,000
The one-time costs for the registration / uplist are estimated at $88,250. The ongoing (annualized) maintenance costs are estimated at $44,000 (inclusive of the Quarterly Reviews by the PCAOB Auditing firm, and the annual year-end report and legal review).
Based on current cash flow and resources - and considering the anticipated benefits to the Company and its shareholders for HHSE as a fully registered equity - the Board has authorized the immediate implementation of this plan and the authorization of these expenditures.
The Board believes that Fully Registered Shares will be more attractive to HHSE program suppliers and investors - as well as to institutional investors and hedge funds - and that pursuing these activities now is a good use of ongoing cash flows.
****
PRODUCT$-PRODUCT$-PRODUCT$. GETTING.GRACE-WHERE'S.THE.DRAGON-BLOODFEAST-DAISY.WINTERS-BATTLECREEK & OTHERS
GETTING GRACE - Hot on the heels of a major NYC Market festival SWEEP of all major awards, HHSE will be releasing this Faith-Based Comedy-Drama nationwide on February 10, 2018 - with an outreach campaign that includes mega-churches and a key-market BUS TOUR with star and director DANIEL ROEBUCK ("Matlock", "The Fugitive") to drive local market enthusiasm.
WHERE'S THE DRAGON - With the dissolution of the merger between HHSE and Crimson Forest, the company is finally cleared to revert back to the terms of the Dec. 2016 distribution agreement for this title. Accordingly, on February 3, 2018, this enchanting Animated Feature will be released to theatres in key markets, in advance of a May, 2018 Home Video and V.O.D. launch.
DEATH HOUSE - A wild horror-comedy from the producer of "Bill & Ted's Bogus Journey" is building strong horror-market enthusiasm from conventions and specialty sites. Opens Jan. 19, 2018 in a yet-undetermined (but significant) number of theatres!
CHOSEN - this impressive World War II thriller continues to get theatrical bookings in key USA markets, and now into CANADA (Toronto, Ottawa, Calgary and Vancouver)... watch for playdates in December and January.
BLOODFEAST - Now that the MPAA has approved our fourth edit for "R-Rating Status" - we can FINALLY get mainstream theatres to book this picture... watch for a roll-out beginning Nov. 17 into top markets (staggered over a 2-month period).
DAISY WINTERS - a much broader release (over 100 theatres) is set for December 1st for this awards-worthy drama featuring stunning performances from Brooke Shields and a breakout performance from young Sterling Jerins in the title role. The Media support has already begun, fueled by the Hannover House MEDIA DAY in NYC on Sept. 26, plus a special event premiere at the Regal Union Square (NYC) on Oct. 5. Already, Brooke has appeared on several national talk shows promoting DAISY WINTERS, including Bravo's WATCH WHAT HAPPENS LIVE and the highly rated TODAY SHOW on NBC. Much more to come, including major feature stories in People Magazine, USA Today, Closer, In-Touch, ACCESS HOLLYWOOD, EXTRA and E! TV.
BATTLECREEK - the acclaimed dramatic thriller from director ALISON EASTWOOD opens in two weeks (Nov. 3), in approx. 20 locations in key USA Markets. The film's primary star is BILL SKARSGARD, well-known from his current smash hit "IT" (he plays Pennywise, the scary clown), and his upcoming Stephen King TV series, "Castlerock." We have been fortunate to receive major media support for BATTLECREEK, including National TV show placements on: ACCESS HOLLYWOOD, EXTRA, E! and ENTERTAINMENT TONIGHT, and Alison Eastwood interview appearances on FOX AND FRIENDS, THE VIEW, TALK, GOOD DAY NY and HOME AND FAMILY. There will be an "Eastwood Family Screening Event" in Los Angeles on opening night (Nov. 3), which will be open to the public (and is expected to generate good attendance).
http://hannoverhousemovies.blogspot.com/
HHSE will have its biggest December ever, THANKS TO BATTLECREEK and BILL SKARSGARD OF THE BLOCKBUSTER $350m+ MOVIE "it". 2017Q4 REVENUES WILL REFLECT. DAISY WINTERS IN THE NEXT POST THEATRICAL MONEYMAKER for HHSE
Stockholders are long and strong! Go Eric! Go HHSE!
http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html
SELDOM DOES A $0.10-$0.30 STOCK TRADE BELOW $0.02. TREMENDOUSLY UNDERVALUED. A GREAT BUYING OPPORTUNITY FOR ANYONE NOT ALREADY LOADED WITH SHARES AND READY FOR THE TAKE-OFF.
LONGS HAVE THE FLOAT LOCKED
FORM 10, AUDIT, UPLIST - STARTING JANUARY 2018
http://hannoverhousemovies.blogspot.com/
Thoughts on the HHSE Stock Chart: The company did very little in share issuance for the first two years... and none for the past 2.5-years - as seen by the flat-line of total shares in issue.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog over the holidays, and watch for news releases occurring between Christmas and New Years, as well as during the first week of January. Happy Holidays / Merry Christmas / Happy New Year and Best Wishes to all our HHSE shareholders!
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
HHSE- What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
Where we have been... Where we are now... and Where we are going at HHSE
Greetings HHSE Friends & Followers:
As we reflect back on 2017, HHSE Management is taking a few days to look at our past, present and future activities to help guide sage decisions. 2017 has been a momentous year for the company - due in large part to the attempted (but terminated) merger with Crimson Forest, and the subsequent re-focus of the company's primary activities and revenue streams.
Looking much further back - five, six, seven years and more - and looking forward in time for an equal time-frame, we can see trends and opportunities for HHSE and our shareholders.
First of all, we'd like to point out that Hannover House is unlike most any other "OTC Pinksheet" listed company. We have been operating continuously since 1993 (24-years) and have been reporting to the OTC Markets since Dec. 2009 (8-years). Statistically, most OTC listed equities are flashes-in-the-pan time wise... lots of Stock Hype / I.R. Promotions, insider share dumps, and quick closures. That's definitely not HHSE.
As a result of this general trend for Pinksheet companies, a whole sub-industry of stock manipulators has developed that can impact OTC-Pinksheet listed companies (for the entirety of OTC markets in general, not specifically limited to Hannover House). Like a gang of drunken hobos in public park - mumbling to each other with insane prognostications - the stock hobos are only effective against low-information shareholders gullible enough to actually read the chat-board postings of manipulative and fact-free ramblings.
Fortunately, every false statement made by the stock hobos or those manipulators attempting to "box" or otherwise control the HHSE stock price, can be easily countered with demonstrable facts.
So, let's take a few minutes to take a high-altitude look at the Company and where we are going.
WHAT IS OUR PLAN FOR GROWTH IN 2018 AND BEYOND?
* We believe that HHSE is "one film away" from being a major independent studio. All it takes is any one of the many titles in our current release queue to become a surprise box officer performer such as "Lady Bird" or "Get Out" and we are suddenly a $100-MM company.
* We have an impressive slate of titles for 2018 and 2019 - and two terrific distribution partners for North America (Cinedigm Entertainment and Sony Pictures Home Entertainment) - as well as our direct relationships with all of the major theatre exhibition chains. Our "lower-end" titles are much higher profile than in past years... and our higher-end titles are now genuine theatrical caliber contenders. We are positioned for the proverbial lucky break that happens when the right film is released at the right time...
* Our recently re-focused Theatrical Release model is delivering huge benefits to our ancillary revenues... and our new partnerships with indie labels is providing access for the VODWIZ streaming venture, which truly could become "the tail that wagged the dog" for HHSE shareholders.
OF UTMOST IMPORTANCE: MUST READ: UPLIST - While HHSE does need to "uplist" - we DON'T need to do a corporate-merger with another entity to achieve this goal. We were enticed by the offer of working capital and access to production funds from Crimson Forest, and thus our long, slow-dance this past year to try and complete a corporate merger. But in the end, we have determined that we do NOT need to dilute our shareholders by 42% (or any amount) in order to become fully registered and uplisted. Fortunately, the time we spent attempting to complete the Crimson merger enabled HHSE to get our audit materials and records in order to quickly facilitate a re-filing of our Form 10 Registration promptly following 12-31-17.
SELDOM DOES A $0.10-$0.30 STOCK TRADE BELOW $0.02. TREMENDOUSLY UNDERVALUED. A GREAT BUYING OPPORTUNITY FOR ANYONE NOT ALREADY LOADED WITH SHARES AND READY FOR THE TAKE-OFF.
LONGS HAVE THE FLOAT LOCKED
FORM 10, AUDIT, UPLIST - STARTING JANUARY 2018
http://hannoverhousemovies.blogspot.com/
FORM10-AUDIT-UPLIST: A PROCESS, NOT A ONE-DAY EVENT, BUT EVERYONE ALREADY KNOWS THAT. THERE IS A 60-DAY SEC REVIEW PERIOD (POSSIBLY FASTER) BEFORE HHSE UPLISTS TO OTCQB. THEREFORE, IT'S ACCURATE TO SAY THE PROCESS IS "STARTING" IN JANUARY. BUT, EVERYONE ALREADY KNEW THAT. LOL
AUDITED 2016 FINANCIALS
UPDATED LIBRARY VALUATION
AUDITED 2017 FINANCIALS
AUDIT LETTER - FORM 10
SEC REVIEW (60 DAYS MAX)
UPLIST TO OTCQB
http://hannoverhousemovies.blogspot.com/
FACT:HHSE IS RID OF AMITYVILLE ($300K). THIS WAS SUPPOSED TO BK THE COMPANY. LMAO.
FACT:HHSE IS RID OF TCA ($400K). THIS WAS SUPPOSED TO BK THE COMPANY. LOL
SELDOM DOES A $0.10-$0.30 STOCK TRADE BELOW $0.02. TREMENDOUSLY UNDERVALUED
Stockholders are long and strong! Go Eric! Go HHSE!
HHSE OTCQB UPLIST In 2018: With No Dilution
* AUDITED 2016 FINANCIALS
* UPDATED LIBRARY VALUATION
* AUDITED 2017 FINANCIALS
* AUDIT LETTER - FORM 10
* SEC REVIEW (60 DAYS MAX)
* UPLIST TO OTCQB
Stockholders are long and strong! Go Eric! Go HHSE!
http://hannoverhousemovies.blogspot.com/
GOOD PRODUCT SELLS - U.S. Theatrical Exhibitors and Video Retailers have proven that they WILL strongly support "quality" films with production values, recognized stars and good performances. Case in point: our tiny theatrical release of "BATTLECREEK" has now sparked RECORD home video pre-orders for Hannover House - with placements at WALMART, TARGET, BEST BUY, FAMILY VIDEO and "awaiting" final approval from REDBOX. This is the first HHSE video heavily supported by TARGET in five years! Our advanced-buzz for "DAISY WINTERS" suggests even more impressive results are likely to follow!
FORM 10, AUDIT, UPLIST - STARTING JANUARY 2018
During the Merger Process with Crimson Forest, Company purposely delayed the release of five (5) new release Home Video and V.O.D. titles, which will be released later in 2017. Company projects that the gross revenue value of the delayed titles is approx. $750,000.
BATTLECREEK will be the largest new release video shipment since 20th Century Fox Home Video shipped over 250,000 units of "TWELVE" for HHSE back in January, 2011. Because of what happened THIS WEEKEND with BATTLECREEK in theatres, HHSE will have our biggest December ever.
Successfully releasing independent films is a strategy and process involving multiple revenues streams and steps to achieve the best, bottom-line result. We are happy with the launch of BATTLECREEK, and know that our year-end financials will demonstrate the validity of this strategy.
Although the Crimson merger will not occur, the uplist will proceed, and the maturation of the company to "the next level" is already well underway. We are now partnered with a Major Studio for distribution; we're Executive Producers / Worldwide Distributors on two CURRENT productions; we have two major titles in theatrical release (Nov. 3 and Dec. 1) and four "genre'" titles for more limited release in the next few months (see below); we have more than doubled the title library for VODWIZ, and partnered with the world's leading digital services operator (Amazon); we have new release DVD and BluRays in the pipeline for February, March, April and May (collectively generating over $4-million in gross shipments), and we are in final documentation of major financing agreements to cover the epic productions of MOTHER GOOSE and MELTDOWN (each of which is transformative in what they will do for HHSE's profile and revenues).
Then there is new Sony Distribution Pact set to kick in 2018
Some where along this path:
* Form 10 (Jan/Feb)
* HHSE OTCQB (after Form 10, SEC 60 day Review)
HHSE: Where we have been... Where we are now... and Where we are going at HHSE...
1). Hannover House has Not Issued any Shares in 2.5-years. See the chart below. For the company's first two years as a public equity, the stock structure was quite stable. For the past 2-1/2 years, the stock structure has also been stable. But in 2013 and 2014, the company got involved in some ugly predatory lender situations, most notably TCA Global and JSJ, which precipitated a rapid growth in share issuances. The business model for both TCA and JSJ - as exercised against HHSE and many other borrowers - is to make repayment with cash as difficult as possible, in order to force a "conversion of the debt" into freely trading shares of the issueer at a dramatic discount-to-market. Such returns grossly exceed the legal usury law limitations in all states, and this general business practice is operating in a legally dubious space. JSJ, for instance, refused to accept repayment from HHSE via a bank wire transfer (including all applicable, legal interest per the note), preferring instead to file a lawsuit (in Texas?!), in order to try to force repayment via shares at 200% or more interest. These predatory lenders generally prey on companies that are unable to defend themselves, and therefore are forced to allow the lenders to squeeze out profits far in excess of lending laws through toxic-conversions; most of the time, these small borrowers are ultimately forced out of business. However, this was not the case with Hannover House - as the company has a operating business that is unaffected by fluctuations of our stock price and not dependent on the issuance of shares for capital. These toxic dilutions from 2013 and 2014 definitely hurt our shareholders, and hurt our "market cap," as demonstrated in the charts. So, the Board voted to cease such forms of borrowing, and as a result, HHSE has not issued any new shares in 2.5-years. Anyone predicting on a chat board or anywhere else that a "big dilution is coming" is mistaken.
2). It Doesn't Take Much to Double or Triple the HHSE Share Price - Look at the market-cap spike for HHSE stock earlier this year (seen as June, 2017). This increase in PPS was due to shareholder excitement about the prospect that a merger with Crimson Forest would provide HHSE with high-profile films to distribute. The growth in PPS was not based on any increase in revenues (in fact, the time-distraction of the Crimson merger caused many 2017 releases to be delayed). The PPS spike was driven solely by enthusiasm.
3). Does HHSE Need a Merger Partner? - If the right opportunity came along that would provide HHSE with a reliable source of high-end theatrical titles, we would be responsive to consider such opportunities. However, the programing philosphy ultimately revealed by Crimson Forest did not conform to North American market conditions, in HHSE's opinion. When the promised operating funding didn't materialize, the promised high-end productions turned into low-end films, and the promised "big" releases all turned out to be Mandarin-language releases, we knew that the partnership would not deliver what HHSE wanted for our step-up to major independent status.
4). What's in Store for the first half of 2018?
a). Release Activities: January will see the theatrical release of "BLOODFEAST" - delayed since July due to MPAA re-cut needs. February will see a massive placement of DVDs and BluRays for "BATTLECREEK" (street date Feb. 6). That same week, on Friday (Feb. 9), HHSE will commence the initla theatrical launch of "DEATH HOUSE" to theatres. In April, three titles will be released via Sony Pictures Home Entertainment (including "DAISY WINTERS" ; in May, HHSE will release "THE RIOT ACT" to theatres and Cinedigm will release DVD's and BluRays of "THE LENNON PROJECT" for the Company. Other titles in queue for theatrical and / or home video during the first half of 2018 include "MUSE", "INSOMNIUM", "IDENTITY CRISIS", "SLEEPER CELL", "DINOSAURS OF THE JURASSIC" and "SACRED HEARTS" (all but the last title were planned for 2017, but delayed during the Crimson merger pursuit).
b). Corporate Governance: HHSE will be re-filing a Form 10 Registration with two full years of audits (2016 and 2017) early this coming year, during the first few weeks; the CPA review is already underway and much of the documentation and procedural steps for the audit were already assembled during 2017 while planning for the Crimson merger. We feel that a registration of the shares and the subsequent uplist to OTC:QB will attract more investors and some institutional funds... resulting in a higher anticipated daily trading volume, and a predicted much higher HHSE stock price (based on business results, industry fundamentals and the proven power of Shareholder Enthusiasm).
c). New Ventures - With Sony and Cinedigm handling selected HHSE releases, our management time can be redirected towards theatrical releases, higher-end acquisitions (including productions) and our VODWIZ streaming venture. As will be seen in our 2017 filings, theatrical release activities are the engine that is now driving HHSE revenues in all other arenas. Theatrical titles get more shelf space and priority placement when released to home video; theatrical titles get larger license fees from Netflix and Television licensors; and theatrical titles provide two direct revenue streams for HHSE in the form of both servicing fees and revenue participations. The current mass merchant and key video retail support for "BATTLECREEK" evidences the sales boost that a targeted, limited theatrical release can deliver for the subsequent home video release.
The next interesting item of note is the tremendous PPS Spike that occurred earlier this year, at which time the Market Cap jumped from $5.4-MM to $24-MM in just a few month's time. What's interesting about this result is that the company was functionally frozen from new releases during that time, so the sudden shareholder enthusiasm cannot be attributed to improved revenues... it can only be viewed as a reaction to the prospective merger with Crimson. The current Market Cap of $12.4-MM has been stable for quite a few months now.
A third observation can be seen during the "heavy dilution" time-frames of 2013 to the end of 2015, when TCA (via MAGNA) and JSJ were flooding the market with toxic-conversion shares. What is interesting about this? Well, the market cap stayed surprisingly stable during this dilution... meaning that the average PPS went DOWN while the total float went UP, but the overall Market Cap remained steady. HHSE Management believes that the Market Cap remained relatively steady during these dilution times due to Investor Relations / Stock Promotions. As the toxic-lenders dumped their HHSE shares onto the market, some effort was being expended (by them or third parties) to create an investor market for their share dumps... which is another reason why HHSE management hates the concept of these toxic-conversion notes. It also answers the question that some shareholders have posted to HHSE management over the past few years about "why aren't you doing IR / Stock PR now?" The answer is that we are are focused on building the fundamentals of the business rather than on creating a momentary spike in PPS interest while some third party lender dumps out shares. We are not philosophically opposed to I.R. and new investor outreach. We just feel that the cost of such promotions would be best utilized after our Registration and other major events in the works.
There are more thoughts and developments to share... watch this blog over the holidays, and watch for news releases occuring between Christmas and New Years, as well as during the first week of January. Happy Holidays / Merry Christmas / Happy New Year and Best Wishes to all our HHSE shareholders!
http://hannoverhousemovies.blogspot.com/2017/...w-and.html
HHSE: FORM10-AUDIT-UPLIST: A PROCESS, NOT A ONE-DAY EVENT, BUT EVERYONE ALREADY KNOWS THAT. THERE IS A 60-DAY SEC REVIEW PERIOD (POSSIBLY FASTER) BEFORE HHSE UPLISTS TO OTCQB. THEREFORE, IT'S ACCURATE TO SAY THE PROCESS IS "STARTING" IN JANUARY. BUT, EVERYONE ALREADY KNEW THAT. LOL
http://hannoverhousemovies.blogspot.com/
AUDITED 2016 FINANCIALS
UPDATED LIBRARY VALUATION
AUDITED 2017 FINANCIALS
AUDIT LETTER - FORM 10
SEC REVIEW (60 DAYS MAX)
UPLIST TO OTCQB
SELDOM DOES A $0.10-$0.30 STOCK TRADE BELOW $0.02. TREMENDOUSLY UNDERVALUED
Stockholders are long and strong! Go Eric! Go HHSE!
HHSE-DAISY WINTERS WILL EASILY MAKE $2.5M+ FROM POST-THEATRICAL REVENUE SOURCES SUCH AS DVDS, BLUE RAYS, TV AND VOD (NETFLIX, VODWIZ, ETC). AS EVERYONE KNOWS, A THEATRICAL RELEASE SIMPLY SATISFIES REQUIREMENTS AND GREATLY AMPLIFIES LIFETIME REVENUES OF A TITLE.
"BATTLECREEK" PROVED THAT POST-THEATRICAL PROCEEDS ARE WHAT MATTER. THEATRICAL RELEASE OF SMALL INDIE MOVIES ARE JUST PRE-REQUISITES FOR MUCH LARGER PROFITS FROM DVD, BLUE RAY, VOD AND TV REVENUES. JUST LOOK AT THE RATIO OF BATTLECREEK PROCEEDS FROM BOX OFFICE VS. $1M+ PROCEEDS FROM POST-THEATRICAL REVENUES.
BUT EVERYONE ALREADY KNEW THIS, SINCE IT WAS CLEARLY EXPLAINED IN THE BLOGS AND PROVEN IN THE MARKETPLACE MANY TIMES.
http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html
How major? Well - based on video preorders already received from Walmart, Target, Best Buy, K-Mart and Family Video - BATTLECREEK will be the largest new release video shipment since 20th Century Fox Home Video shipped over 250,000 units of "TWELVE" for HHSE back in January, 2011. Because of what happened THIS WEEKEND with BATTLECREEK in theatres, HHSE will have our biggest December ever.
HHSE Board of Directors approves Uplisting / Registration Costs
http://hannoverhousemovies.blogspot.com/
Dear HHSE Friends, Followers & Shareholders: At a special meeting of the Board of Directors of Hannover House, Inc., held on Thursday, October 19 at 11:00-am, the Board voted unanimously to immediately reinstate the prior filing activities to register the company's stock shares with the Securities and Exchange Commission (Form 10). The Board also authorized the following budgetary expenditures - to be funded from ongoing cash flows - to promptly complete this task:
HHSE
Steps and Budget for UPLISTING
Item
Description
Amount
1
Internal Data Entry
$ 4,000
2
Completion of New Library Valuation
$ 20,000
3
Outside CPA Review
$ 4,500
4
PCAOB Audit
$ 50,000
5
Legal Review & Drafting
$ 6,500
6
Registration S.E.C. Filings & XBRL
$ 3,250
FIRST TIME - UPLIST REGISTRATION COSTS
$ 88,250
Ongoing Quarterly Auditor's Review
$ 5,000
Ongoing Quarterly Attorney's Review
$ 2,000
Annual Review of Q4 & prior 3-Q's
$ 20,000
Annual Attorney review and drafting
$ 3,000
ANNUAL MAINTENANCE TOTALS
$ 44,000
The one-time costs for the registration / uplist are estimated at $88,250. The ongoing (annualized) maintenance costs are estimated at $44,000 (inclusive of the Quarterly Reviews by the PCAOB Auditing firm, and the annual year-end report and legal review).
Based on current cash flow and resources - and considering the anticipated benefits to the Company and its shareholders for HHSE as a fully registered equity - the Board has authorized the immediate implementation of this plan and the authorization of these expenditures.
The Board believes that Fully Registered Shares will be more attractive to HHSE program suppliers and investors - as well as to institutional investors and hedge funds - and that pursuing these activities now is a good use of ongoing cash flows.
****
PRODUCT$-PRODUCT$-PRODUCT$. GETTING.GRACE-WHERE'S.THE.DRAGON-BLOODFEAST-DAISY.WINTERS-BATTLECREEK & OTHERS
GETTING GRACE - Hot on the heels of a major NYC Market festival SWEEP of all major awards, HHSE will be releasing this Faith-Based Comedy-Drama nationwide on February 10, 2018 - with an outreach campaign that includes mega-churches and a key-market BUS TOUR with star and director DANIEL ROEBUCK ("Matlock", "The Fugitive") to drive local market enthusiasm.
WHERE'S THE DRAGON - With the dissolution of the merger between HHSE and Crimson Forest, the company is finally cleared to revert back to the terms of the Dec. 2016 distribution agreement for this title. Accordingly, on February 3, 2018, this enchanting Animated Feature will be released to theatres in key markets, in advance of a May, 2018 Home Video and V.O.D. launch.
DEATH HOUSE - A wild horror-comedy from the producer of "Bill & Ted's Bogus Journey" is building strong horror-market enthusiasm from conventions and specialty sites. Opens Jan. 19, 2018 in a yet-undetermined (but significant) number of theatres!
CHOSEN - this impressive World War II thriller continues to get theatrical bookings in key USA markets, and now into CANADA (Toronto, Ottawa, Calgary and Vancouver)... watch for playdates in December and January.
BLOODFEAST - Now that the MPAA has approved our fourth edit for "R-Rating Status" - we can FINALLY get mainstream theatres to book this picture... watch for a roll-out beginning Nov. 17 into top markets (staggered over a 2-month period).
DAISY WINTERS - a much broader release (over 100 theatres) is set for December 1st for this awards-worthy drama featuring stunning performances from Brooke Shields and a breakout performance from young Sterling Jerins in the title role. The Media support has already begun, fueled by the Hannover House MEDIA DAY in NYC on Sept. 26, plus a special event premiere at the Regal Union Square (NYC) on Oct. 5. Already, Brooke has appeared on several national talk shows promoting DAISY WINTERS, including Bravo's WATCH WHAT HAPPENS LIVE and the highly rated TODAY SHOW on NBC. Much more to come, including major feature stories in People Magazine, USA Today, Closer, In-Touch, ACCESS HOLLYWOOD, EXTRA and E! TV.
BATTLECREEK - the acclaimed dramatic thriller from director ALISON EASTWOOD opens in two weeks (Nov. 3), in approx. 20 locations in key USA Markets. The film's primary star is BILL SKARSGARD, well-known from his current smash hit "IT" (he plays Pennywise, the scary clown), and his upcoming Stephen King TV series, "Castlerock." We have been fortunate to receive major media support for BATTLECREEK, including National TV show placements on: ACCESS HOLLYWOOD, EXTRA, E! and ENTERTAINMENT TONIGHT, and Alison Eastwood interview appearances on FOX AND FRIENDS, THE VIEW, TALK, GOOD DAY NY and HOME AND FAMILY. There will be an "Eastwood Family Screening Event" in Los Angeles on opening night (Nov. 3), which will be open to the public (and is expected to generate good attendance).
HHSE-SELDOM DOES A $0.10-$0.30 STOCK TRADE BELOW $0.02. TREMENDOUSLY UNDERVALUED. A GREAT BUYING OPPORTUNITY FOR ANYONE NOT ALREADY LOADED WITH SHARES AND READY FOR THE TAKE-OFF.
HHSE-OF UTMOST IMPORTANCE: MUST READ: UPLIST - While HHSE does need to "uplist" - we DON'T need to do a corporate-merger with another entity to achieve this goal. We were enticed by the offer of working capital and access to production funds from Crimson Forest, and thus our long, slow-dance this past year to try and complete a corporate merger. But in the end, we have determined that we do NOT need to dilute our shareholders by 42% (or any amount) in order to become fully registered and uplisted. Fortunately, the time we spent attempting to complete the Crimson merger enabled HHSE to get our audit materials and records in order to quickly facilitate a re-filing of our Form 10 Registration promptly following 12-31-17.
OF UTMOST IMPORTANCE: MUST READ: UPLIST - While HHSE does need to "uplist" - we DON'T need to do a corporate-merger with another entity to achieve this goal. We were enticed by the offer of working capital and access to production funds from Crimson Forest, and thus our long, slow-dance this past year to try and complete a corporate merger. But in the end, we have determined that we do NOT need to dilute our shareholders by 42% (or any amount) in order to become fully registered and uplisted. Fortunately, the time we spent attempting to complete the Crimson merger enabled HHSE to get our audit materials and records in order to quickly facilitate a re-filing of our Form 10 Registration promptly following 12-31-17.
http://hannoverhousemovies.blogspot.com/
SELDOM DOES A $0.10-$0.30 STOCK TRADE BELOW $0.02. TREMENDOUSLY UNDERVALUED. A GREAT BUYING OPPORTUNITY FOR ANYONE NOT ALREADY LOADED WITH SHARES AND READY FOR THE TAKE-OFF.
LONGS HAVE THE FLOAT LOCKED
FORM 10, AUDIT, UPLIST - STARTING JANUARY 2018
HHSE MANAGEMENT'S RECENT SILENCE SPEAKS VOLUMES!!!!!!!!!!!!!!!
LOTS TO BE UNLEASHED IN COMING FEW WEEKS!!!!!!!!!!!!!!!
SHORTS NERVOUS - *****FLOAT LOCKED*****
HHSE will have its biggest December ever, THANKS TO BATTLECREEK and BILL SKARSGARD OF THE BLOCKBUSTER $350m+ MOVIE "it". 2017Q4 REVENUES WILL REFLECT. DAISY WINTERS IN THE NEXT POST THEATRICAL MONEYMAKER for HHSE
Stockholders are long and strong! Go Eric! Go HHSE!
http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html
HHSE Board of Directors approves Uplisting / Registration Costs
Dear HHSE Friends, Followers & Shareholders: At a special meeting of the Board of Directors of Hannover House, Inc., held on Thursday, October 19 at 11:00-am, the Board voted unanimously to immediately reinstate the prior filing activities to register the company's stock shares with the Securities and Exchange Commission (Form 10). The Board also authorized the following budgetary expenditures - to be funded from ongoing cash flows - to promptly complete this task:
HHSE
Steps and Budget for UPLISTING
Item
Description
Amount
1
Internal Data Entry
$ 4,000
2
Completion of New Library Valuation
$ 20,000
3
Outside CPA Review
$ 4,500
4
PCAOB Audit
$ 50,000
5
Legal Review & Drafting
$ 6,500
6
Registration S.E.C. Filings & XBRL
$ 3,250
FIRST TIME - UPLIST REGISTRATION COSTS
$ 88,250
Ongoing Quarterly Auditor's Review
$ 5,000
Ongoing Quarterly Attorney's Review
$ 2,000
Annual Review of Q4 & prior 3-Q's
$ 20,000
Annual Attorney review and drafting
$ 3,000
ANNUAL MAINTENANCE TOTALS
$ 44,000
The one-time costs for the registration / uplist are estimated at $88,250. The ongoing (annualized) maintenance costs are estimated at $44,000 (inclusive of the Quarterly Reviews by the PCAOB Auditing firm, and the annual year-end report and legal review).
Based on current cash flow and resources - and considering the anticipated benefits to the Company and its shareholders for HHSE as a fully registered equity - the Board has authorized the immediate implementation of this plan and the authorization of these expenditures.
The Board believes that Fully Registered Shares will be more attractive to HHSE program suppliers and investors - as well as to institutional investors and hedge funds - and that pursuing these activities now is a good use of ongoing cash flows.
****
PRODUCT$-PRODUCT$-PRODUCT$. GETTING.GRACE-WHERE'S.THE.DRAGON-BLOODFEAST-DAISY.WINTERS-BATTLECREEK & OTHERS
GETTING GRACE - Hot on the heels of a major NYC Market festival SWEEP of all major awards, HHSE will be releasing this Faith-Based Comedy-Drama nationwide on February 10, 2018 - with an outreach campaign that includes mega-churches and a key-market BUS TOUR with star and director DANIEL ROEBUCK ("Matlock", "The Fugitive") to drive local market enthusiasm.
WHERE'S THE DRAGON - With the dissolution of the merger between HHSE and Crimson Forest, the company is finally cleared to revert back to the terms of the Dec. 2016 distribution agreement for this title. Accordingly, on February 3, 2018, this enchanting Animated Feature will be released to theatres in key markets, in advance of a May, 2018 Home Video and V.O.D. launch.
DEATH HOUSE - A wild horror-comedy from the producer of "Bill & Ted's Bogus Journey" is building strong horror-market enthusiasm from conventions and specialty sites. Opens Jan. 19, 2018 in a yet-undetermined (but significant) number of theatres!
CHOSEN - this impressive World War II thriller continues to get theatrical bookings in key USA markets, and now into CANADA (Toronto, Ottawa, Calgary and Vancouver)... watch for playdates in December and January.
BLOODFEAST - Now that the MPAA has approved our fourth edit for "R-Rating Status" - we can FINALLY get mainstream theatres to book this picture... watch for a roll-out beginning Nov. 17 into top markets (staggered over a 2-month period).
DAISY WINTERS - a much broader release (over 100 theatres) is set for December 1st for this awards-worthy drama featuring stunning performances from Brooke Shields and a breakout performance from young Sterling Jerins in the title role. The Media support has already begun, fueled by the Hannover House MEDIA DAY in NYC on Sept. 26, plus a special event premiere at the Regal Union Square (NYC) on Oct. 5. Already, Brooke has appeared on several national talk shows promoting DAISY WINTERS, including Bravo's WATCH WHAT HAPPENS LIVE and the highly rated TODAY SHOW on NBC. Much more to come, including major feature stories in People Magazine, USA Today, Closer, In-Touch, ACCESS HOLLYWOOD, EXTRA and E! TV.
BATTLECREEK - the acclaimed dramatic thriller from director ALISON EASTWOOD opens in two weeks (Nov. 3), in approx. 20 locations in key USA Markets. The film's primary star is BILL SKARSGARD, well-known from his current smash hit "IT" (he plays Pennywise, the scary clown), and his upcoming Stephen King TV series, "Castlerock." We have been fortunate to receive major media support for BATTLECREEK, including National TV show placements on: ACCESS HOLLYWOOD, EXTRA, E! and ENTERTAINMENT TONIGHT, and Alison Eastwood interview appearances on FOX AND FRIENDS, THE VIEW, TALK, GOOD DAY NY and HOME AND FAMILY. There will be an "Eastwood Family Screening Event" in Los Angeles on opening night (Nov. 3), which will be open to the public (and is expected to generate good attendance).
Thursday, December 21, 2017
HHSE VODWIZ welcomes Production Master Technician EARL HALE to our Team!
Greetings Hannover House Friends & Followers - Just in time for the Holidays, we are pleased to announce the engagement of EARL HALE as Technical Services Director for VODWIZ and Hannover House. Earl has an impressive resume in video production, mastering and technical services, including multi-year directorships at Walmart TV and the Media Center of the University of Arkansas Global Campus. A formal press release will post in early January, along with VODWIZ supplier and status news.
Watch this blog for an informative overview on Saturday of Hannover House for the past two years, as well as a sneak-peek into major activities for the company in 2018!
http://hannoverhousemovies.blogspot.com/2017/12/hhse-vodwiz-welcomes-production-master.html
MORE VODWIZ - there's another MAJOR STUDIO ALERT in the works! Over the past three years of development, two Major Studios (each offering a small "test quantity" of titles for VODWIZ), were secured to support the initial launch of this streaming operation. Now, we are poised for a very major development of a third Major Studio with over 500 high-profile, ready-to-place titles available for the VODWIZ streaming platform. HHSE key managers (Fred Shefte and Eric Parkinson) are meeting at the studio in southern California on Friday to discuss the logistics of this venture, which is already documented through a participation term sheet.
VODWIZ UPDATE - As anticipated, we have closed a major studio venture that will provide tonnage of product to VODWIZ, including a large quantity of recent, theatrical hits. The totality of programming that will be available to consumers through VODWIZ appears to be on track to being second only to Amazon at this point. We see VODWIZ as a major portal for home entertainment digital streaming access, and potentially "the tail that wags the dog" so to speak. Additionally, we are about a week away from the anticipated finalization of a private funding structure to finance the costs associated with building the VODWIZ website (to Amazon Digital infrastructure standards), and all other pre-launch and initial consumer launch costs for this venture.
DAISY WINTERS WILL EASILY MAKE $2.5M+ FROM POST-THEATRICAL REVENUE SOURCES SUCH AS DVDS, BLUE RAYS, TV AND VOD (NETFLIX, VODWIZ, ETC). AS EVERYONE KNOWS, A THEATRICAL RELEASE SIMPLY SATISFIES REQUIREMENTS AND GREATLY AMPLIFIES LIFETIME REVENUES OF A TITLE.
"BATTLECREEK" PROVED THAT POST-THEATRICAL PROCEEDS ARE WHAT MATTER. THEATRICAL RELEASE OF SMALL INDIE MOVIES ARE JUST PRE-REQUISITES FOR MUCH LARGER PROFITS FROM DVD, BLUE RAY, VOD AND TV REVENUES. JUST LOOK AT THE RATIO OF BATTLECREEK PROCEEDS FROM BOX OFFICE VS. $1M+ PROCEEDS FROM POST-THEATRICAL REVENUES.
BUT EVERYONE ALREADY KNEW THIS, SINCE IT WAS CLEARLY EXPLAINED IN THE BLOGS AND PROVEN IN THE MARKETPLACE MANY TIMES.
http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html
How major? Well - based on video preorders already received from Walmart, Target, Best Buy, K-Mart and Family Video - BATTLECREEK will be the largest new release video shipment since 20th Century Fox Home Video shipped over 250,000 units of "TWELVE" for HHSE back in January, 2011. Because of what happened THIS WEEKEND with BATTLECREEK in theatres, HHSE will have our biggest December ever.
"BATTLECREEK" IS ALREADY A $1MILLION+ HHSE MOVIE, AND THE REVENUES ARE JUST GETTING STARTED. SECOND LARGEST SHIPMENT EVER FOR HHSE.
http://hannoverhousemovies.blogspot.com/2017/11/battlecreek-theatrical-launch-meeting.html
FORM10-AUDIT-UPLIST: A PROCESS, NOT A ONE-DAY EVENT, BUT EVERYONE ALREADY KNOWS THAT. THERE IS A 60-DAY SEC REVIEW PERIOD (POSSIBLY FASTER) BEFORE HHSE UPLISTS TO OTCQB. THEREFORE, IT'S ACCURATE TO SAY THE PROCESS IS "STARTING" IN JANUARY. BUT, EVERYONE ALREADY KNEW THAT. LOL
AUDITED 2016 FINANCIALS
UPDATED LIBRARY VALUATION
AUDITED 2017 FINANCIALS
AUDIT LETTER - FORM 10
SEC REVIEW (60 DAYS MAX)
UPLIST TO OTCQB
SELDOM DOES A $0.10-$0.30 STOCK TRADE BELOW $0.02. TREMENDOUSLY UNDERVALUED
Stockholders are long and strong! Go Eric! Go HHSE!
FACT:HHSE IS RID OF AMITYVILLE ($300K). THIS WAS SUPPOSED TO BK THE COMPANY. LMAO.
FACT:HHSE IS RID OF TCA ($400K). THIS WAS SUPPOSED TO BK THE COMPANY. LOL
HHSE OTCQB UPLIST In 2018: With No Dilution
* AUDITED 2016 FINANCIALS
* UPDATED LIBRARY VALUATION
* AUDITED 2017 FINANCIALS
* AUDIT LETTER - FORM 10
* SEC REVIEW (60 DAYS MAX)
* UPLIST TO OTCQB
Stockholders are long and strong! Go Eric! Go HHSE!
GOOD PRODUCT SELLS - U.S. Theatrical Exhibitors and Video Retailers have proven that they WILL strongly support "quality" films with production values, recognized stars and good performances. Case in point: our tiny theatrical release of "BATTLECREEK" has now sparked RECORD home video pre-orders for Hannover House - with placements at WALMART, TARGET, BEST BUY, FAMILY VIDEO and "awaiting" final approval from REDBOX. This is the first HHSE video heavily supported by TARGET in five years! Our advanced-buzz for "DAISY WINTERS" suggests even more impressive results are likely to follow!
FORM 10, AUDIT, UPLIST - STARTING JANUARY 2018
(1)During the Merger Process with Crimson Forest, Company purposely delayed the release of five (5) new release Home Video and V.O.D. titles, which will be released later in 2017. Company projects that the gross revenue value of the delayed titles is approx. $750,000.
BATTLECREEK will be the largest new release video shipment since 20th Century Fox Home Video shipped over 250,000 units of "TWELVE" for HHSE back in January, 2011. Because of what happened THIS WEEKEND with BATTLECREEK in theatres, HHSE will have our biggest December ever.
Successfully releasing independent films is a strategy and process involving multiple revenues streams and steps to achieve the best, bottom-line result. We are happy with the launch of BATTLECREEK, and know that our year-end financials will demonstrate the validity of this strategy.
Although the Crimson merger will not occur, the uplist will proceed, and the maturation of the company to "the next level" is already well underway. We are now partnered with a Major Studio for distribution; we're Executive Producers / Worldwide Distributors on two CURRENT productions; we have two major titles in theatrical release (Nov. 3 and Dec. 1) and four "genre'" titles for more limited release in the next few months (see below); we have more than doubled the title library for VODWIZ, and partnered with the world's leading digital services operator (Amazon); we have new release DVD and BluRays in the pipeline for February, March, April and May (collectively generating over $4-million in gross shipments), and we are in final documentation of major financing agreements to cover the epic productions of MOTHER GOOSE and MELTDOWN (each of which is transformative in what they will do for HHSE's profile and revenues).
Then there is new Sony Distribution Pact set to kick in 2018
Some where along this path:
* Form 10 (Jan/Feb)
* HHSE OTCQB (after Form 10, SEC 60 day Review)
HHSE MANAGEMENT'S RECENT SILENCE SPEAKS VOLUMES!!!!!!!!!!!!!!!
LOTS TO BE UNLEASHED IN COMING FEW WEEKS!!!!!!!!!!!!!!!
(1) During the Merger Process with Crimson Forest, Company purposely delayed the release of five (5) new release Home Video and V.O.D. titles, which will be released later in 2017. Company projects that the gross revenue value of the delayed titles is approx. $750,000.
BATTLECREEK will be the largest new release video shipment since 20th Century Fox Home Video shipped over 250,000 units of "TWELVE" for HHSE back in January, 2011. Because of what happened THIS WEEKEND with BATTLECREEK in theatres, HHSE will have our biggest December ever.
Successfully releasing independent films is a strategy and process involving multiple revenues streams and steps to achieve the best, bottom-line result. We are happy with the launch of BATTLECREEK, and know that our year-end financials will demonstrate the validity of this strategy.
Although the Crimson merger will not occur, the uplist will proceed, and the maturation of the company to "the next level" is already well underway. We are now partnered with a Major Studio for distribution; we're Executive Producers / Worldwide Distributors on two CURRENT productions; we have two major titles in theatrical release (Nov. 3 and Dec. 1) and four "genre'" titles for more limited release in the next few months (see below); we have more than doubled the title library for VODWIZ, and partnered with the world's leading digital services operator (Amazon); we have new release DVD and BluRays in the pipeline for February, March, April and May (collectively generating over $4-million in gross shipments), and we are in final documentation of major financing agreements to cover the epic productions of MOTHER GOOSE and MELTDOWN (each of which is transformative in what they will do for HHSE's profile and revenues).
Then there is new Sony Distribution Pact set to kick in 2018
Some where along this path:
* Form 10 (Jan/Feb)
* HHSE OTCQB (after Form 10, SEC 60 day Review)
GOOD PRODUCT SELLS - U.S. Theatrical Exhibitors and Video Retailers have proven that they WILL strongly support "quality" films with production values, recognized stars and good performances. Case in point: our tiny theatrical release of "BATTLECREEK" has now sparked RECORD home video pre-orders for Hannover House - with placements at WALMART, TARGET, BEST BUY, FAMILY VIDEO and "awaiting" final approval from REDBOX. This is the first HHSE video heavily supported by TARGET in five years! Our advanced-buzz for "DAISY WINTERS" suggests even more impressive results are likely to follow!
FORM 10, AUDIT, UPLIST - STARTING JANUARY 2018